Sluggish growth in new demand due to high penetration of the installed base
First written in FY2016. 8 of 9 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「The company's blood collection tube preparation equipment and systems had been installed at more than 2,500 facilities in Japan, and its market share, based on the cumulative number of facilities with installations, has remained around 90% according to the company's estimates.」
Cumulative installed facilities have been updated to more than 2,500 in Japan, while market share has remained around 90%. The company continues to identify the risk of sluggish demand for new installations resulting from its high market share. - FY2024RestatedAnnual report
「The company's blood collection tube preparation equipment and systems had been installed at more than 2,000 facilities, and its market share, based on the cumulative number of facilities with installations, has remained around 90% according to the company's estimates.」
The company continues to identify the risk of sluggish demand for new installations against a structural backdrop of more than 2,000 cumulative installed facilities and market share of around 90%. - FY2023RestatedAnnual report
「The company's blood collection tube preparation equipment and systems had been installed at more than 2,000 facilities, and its market share, based on the cumulative number of facilities with installations, has remained around 90% according to the company's estimates.」
The company continues to identify the risk of sluggish demand for new installations against a backdrop of more than 2,000 cumulative installed facilities and market share of around 90%. - FY2022RestatedAnnual report
「The company's blood collection tube preparation equipment and systems had been installed at more than 2,000 facilities, and its market share, based on the cumulative number of facilities with installations, has remained around 90% according to the company's estimates.」
Against a structural backdrop of more than 2,000 cumulative installed facilities and market share of around 90%, the company continues to identify the risk of sluggish demand for new installations. - FY2021RestatedAnnual report
「The company's blood collection tube preparation equipment had been installed at more than 2,000 facilities, and its market share, based on the cumulative number of facilities with installations, has remained around 90% according to the company's estimates.」
Against a structural backdrop of more than 2,000 cumulative installed facilities and market share of around 90%, the company continues to identify the risk of sluggish demand for new installations. - FY2019RestatedAnnual report
「The company's blood collection tube preparation equipment had been installed at more than 2,000 facilities, and its market share, based on the cumulative number of facilities with installations, has remained around 90% according to the company's estimates.」
Cumulative installed facilities exceeded 2,000 and market share has remained around 90%. The company continues to identify the risk of sluggish demand for new installations resulting from its high market share. - FY2018RestatedAnnual report
「The company's blood collection tube preparation equipment had been installed at 2,021 facilities as of the end of the fiscal year ended March 2018, and its market share, based on the cumulative number of facilities with installations, has remained around 90% according to the company's estimates.」
Cumulative installed facilities increased from 1,971 to 2,021, but market share has remained around 90%, and the company continues to recognize the risk of sluggish demand for new installations. - FY2017RestatedAnnual report
「The company's blood collection tube preparation equipment had been installed at 1,971 facilities as of the end of the fiscal year ended March 2017, and its market share, based on the cumulative number of facilities with installations, has remained around 90% according to the company's estimates.」
Cumulative installed facilities increased to 1,971, but market share has remained around 90%, and the company continues to recognize the risk of sluggish demand for new installations. - FY2016First statedAnnual report
「The company's blood collection tube preparation equipment had been installed at 1,939 facilities as of the end of the fiscal year ended March 2016, and its market share, based on the cumulative number of facilities with installations, has remained around 90% according to the company's estimates. Given the number of large general hospitals with 200 or more beds, which are the company's primary target customers, the number of new installations may stagnate or begin to decline going forward.」
Against a backdrop of 1,939 cumulative installed facilities and an approximately 90% market share, the company identifies stagnant or declining new installations at large hospitals as a risk.